Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
CRMD's Cash-to-Debt is ranked higher than
82% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CRMD: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CRMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.81
CRMD's Equity-to-Asset is ranked higher than
68% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CRMD: 0.81 )
Ranked among companies with meaningful Equity-to-Asset only.
CRMD' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.36  Med: 0.76 Max: 0.92
Current: 0.81
-1.36
0.92
Piotroski F-Score: 3
Altman Z-Score: -6.52
Beneish M-Score: -4.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -11053.57
CRMD's Operating Margin % is ranked lower than
92% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CRMD: -11053.57 )
Ranked among companies with meaningful Operating Margin % only.
CRMD' s Operating Margin % Range Over the Past 10 Years
Min: -245750  Med: -9492.25 Max: -4710.05
Current: -11053.57
-245750
-4710.05
Net Margin % -11001.34
CRMD's Net Margin % is ranked lower than
93% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CRMD: -11001.34 )
Ranked among companies with meaningful Net Margin % only.
CRMD' s Net Margin % Range Over the Past 10 Years
Min: -456650  Med: -10911.74 Max: -8660.95
Current: -11001.34
-456650
-8660.95
ROE % -91.82
CRMD's ROE % is ranked lower than
78% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CRMD: -91.82 )
Ranked among companies with meaningful ROE % only.
CRMD' s ROE % Range Over the Past 10 Years
Min: -678.23  Med: -126.09 Max: -95.1
Current: -91.82
-678.23
-95.1
ROA % -80.71
CRMD's ROA % is ranked lower than
81% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CRMD: -80.71 )
Ranked among companies with meaningful ROA % only.
CRMD' s ROA % Range Over the Past 10 Years
Min: -507.14  Med: -189.63 Max: -83.53
Current: -80.71
-507.14
-83.53
ROC (Joel Greenblatt) % -23335.23
CRMD's ROC (Joel Greenblatt) % is ranked lower than
93% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CRMD: -23335.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CRMD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -53119.48  Med: -39827.19 Max: -25220.83
Current: -23335.23
-53119.48
-25220.83
3-Year EBITDA Growth Rate 5.20
CRMD's 3-Year EBITDA Growth Rate is ranked higher than
55% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CRMD: 5.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CRMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -66.6  Med: 5.2 Max: 30.3
Current: 5.2
-66.6
30.3
3-Year EPS without NRI Growth Rate -2.00
CRMD's 3-Year EPS without NRI Growth Rate is ranked higher than
51% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CRMD: -2.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CRMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.4  Med: -2 Max: 24.6
Current: -2
-68.4
24.6
GuruFocus has detected 3 Warning Signs with Cormedix Inc $CRMD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CRMD Guru Trades in Q1 2016

Paul Singer 1,500,200 sh (unchged)
» More
Q2 2016

CRMD Guru Trades in Q2 2016

Paul Singer 1,500,200 sh (unchged)
» More
Q3 2016

CRMD Guru Trades in Q3 2016

Paul Singer 1,500,200 sh (unchged)
» More
Q4 2016

CRMD Guru Trades in Q4 2016

Paul Singer 1,500,200 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CRMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:VICL, AMEX:CVM, OTCPK:OBMP, NAS:HTBX, NAS:ICCC, NAS:ANTH, OTCPK:PRGB, OTCPK:PRNAF, NAS:NEOT, OTCPK:EMIS, NAS:RPRX, NAS:CATB, NAS:CYTX, NAS:ABIO, NAS:PRTO, NAS:ONCS, NAS:CLRB, OTCPK:USRM, OTCPK:BRTX, OTCPK:ATTBF » details
Traded in other countries:19K.Germany,
Headquarter Location:USA
Cormedix Inc is a commercial-stage biopharmaceutical company. It focuses on development and commercializing prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases.

Cormedix Inc was organized as a Delaware corporation on July 28, 2006 under the name Picton Holding Company, Inc. and changed it to CorMedix Inc. on January 18, 2007. The Company develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Its principal product under development includes CRMD003, an antimicrobial/anticoagulant solution applied in the prevention of catheter related bloodstream infections and maintenance of catheter patency in central venous catheters used for vascular access in hemodialysis patients. Its products also include CRMD004, a pressure sensitive gel that is in pre-clinical Phase.

Ratios

vs
industry
vs
history
PB Ratio 1.45
CRMD's PB Ratio is ranked higher than
50% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CRMD: 1.45 )
Ranked among companies with meaningful PB Ratio only.
CRMD' s PB Ratio Range Over the Past 10 Years
Min: 1.3  Med: 3.72 Max: 31.85
Current: 1.45
1.3
31.85
PS Ratio 128.00
CRMD's PS Ratio is ranked lower than
94% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CRMD: 128.00 )
Ranked among companies with meaningful PS Ratio only.
CRMD' s PS Ratio Range Over the Past 10 Years
Min: 128  Med: 407.14 Max: 2810
Current: 128
128
2810
EV-to-EBIT -0.24
CRMD's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CRMD: -0.24 )
Ranked among companies with meaningful EV-to-EBIT only.
CRMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.6  Med: -2.1 Max: -0.2
Current: -0.24
-22.6
-0.2
EV-to-EBITDA -0.24
CRMD's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CRMD: -0.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.6  Med: -2.1 Max: -0.2
Current: -0.24
-22.6
-0.2
Current Ratio 5.34
CRMD's Current Ratio is ranked higher than
59% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CRMD: 5.34 )
Ranked among companies with meaningful Current Ratio only.
CRMD' s Current Ratio Range Over the Past 10 Years
Min: 0.1  Med: 2.82 Max: 12.11
Current: 5.34
0.1
12.11
Quick Ratio 5.29
CRMD's Quick Ratio is ranked higher than
60% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CRMD: 5.29 )
Ranked among companies with meaningful Quick Ratio only.
CRMD' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 2.65 Max: 11.98
Current: 5.29
0.1
11.98
Days Inventory 230.17
CRMD's Days Inventory is ranked lower than
76% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. CRMD: 230.17 )
Ranked among companies with meaningful Days Inventory only.
CRMD' s Days Inventory Range Over the Past 10 Years
Min: 72.28  Med: 246.36 Max: 480.56
Current: 230.17
72.28
480.56
Days Sales Outstanding 19.55
CRMD's Days Sales Outstanding is ranked higher than
84% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CRMD: 19.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.55  Med: 259.75 Max: 549.24
Current: 19.55
19.55
549.24
Days Payable 1.00
CRMD's Days Payable is ranked lower than
98% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. CRMD: 1.00 )
Ranked among companies with meaningful Days Payable only.
CRMD' s Days Payable Range Over the Past 10 Years
Min: 730.82  Med: 1667.28 Max: 1955.44
Current: 1
730.82
1955.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -34.50
CRMD's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CRMD: -34.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -137  Med: -34.5 Max: -13.3
Current: -34.5
-137
-13.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.60
CRMD's Price-to-Net-Cash is ranked higher than
69% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. CRMD: 1.60 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CRMD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.26  Med: 3.83 Max: 14.69
Current: 1.6
2.26
14.69
Price-to-Net-Current-Asset-Value 1.46
CRMD's Price-to-Net-Current-Asset-Value is ranked higher than
70% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. CRMD: 1.46 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CRMD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.16  Med: 2.89 Max: 11.94
Current: 1.46
2.16
11.94
Price-to-Tangible-Book 1.45
CRMD's Price-to-Tangible-Book is ranked higher than
57% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CRMD: 1.45 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CRMD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.15  Med: 2.86 Max: 11.79
Current: 1.45
2.15
11.79
Price-to-Median-PS-Value 0.31
CRMD's Price-to-Median-PS-Value is ranked higher than
67% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CRMD: 0.31 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRMD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.52  Med: 0.71 Max: 0.75
Current: 0.31
0.52
0.75
Earnings Yield (Greenblatt) % -416.67
CRMD's Earnings Yield (Greenblatt) % is ranked lower than
92% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CRMD: -416.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRMD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5437.8  Med: 0 Max: 0
Current: -416.67
-5437.8
0

More Statistics

Revenue (TTM) (Mil) $0.22
EPS (TTM) $ -0.64
Beta2.35
Short Percentage of Float8.75%
52-Week Range $0.63 - 4.50
Shares Outstanding (Mil)40.72

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1 5
EPS ($) -0.53 -0.45 -0.30
EPS without NRI ($) -0.53 -0.45 -0.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CRMD

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in CorMed Aug 07 2015 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CorMedix, Inc. of Pendency of Clas Jul 16 2015 
Paul Singer's Latest Portfolio Increases and Reduction Mar 04 2015 
CorMedix Receives Approval From FDA to Initiate a Clinical Trial for Neutrolin in the US Oct 27 2014 
Weekly CFO Buys Highlight: CEP, JNS, CRMD, VAC, TICC Dec 26 2011 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
CORMEDIX INC Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
CorMedix Inc. Increases Previously Announced Public Offering to $12.1 Million Apr 28 2017
CorMedix Inc. Announces $10 Million Underwritten Public Offering Apr 27 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of... Apr 24 2017
CorMedix Inc. Reports Update on Neutrolin(R) Phase 3 LOCK-IT 100 Clinical Trial Apr 20 2017
CorMedix Inc. Secures First European Commercial Collaboration for Neutrolin(R) Apr 12 2017
ETFs with exposure to CorMedix, Inc. : April 10, 2017 Apr 10 2017
Are Options Traders Betting on a Big Move in CorMedix (CRMD) Stock? Mar 30 2017
CorMedix Inc. Makes NYSE MKT Section 610(b) Public Announcement Mar 23 2017
CorMedix, Inc. :CRMD-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
CorMedix's stock plunges after warning that it may run out of cash Mar 17 2017
CorMedix Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business... Mar 17 2017
CorMedix Inc. to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Business... Mar 10 2017
CorMedix Inc. Appoints John L. (Jack) Armstrong to Senior Leadership Team Mar 02 2017
CorMedix Inc. Announces New Appointments to Senior Leadership Team Feb 01 2017
ETFs with exposure to CorMedix, Inc. : January 19, 2017 Jan 19 2017
Is the Options Market Predicting a Spike in CorMedix (CRMD) Stock? Jan 18 2017
CorMedix Inc. Announces Dismissal of Shareholder Derivative Action Lawsuit and Stipulation to Forego... Jan 09 2017
CorMedix to Present at Biotech Showcase 2017 Jan 05 2017
CorMedix Inc. Announces Dismissal of Securities Class Action Lawsuit and Stipulation to Forego... Dec 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)